RESUMEN
INTRODUCTION: Postpartum anaemia is often caused by iron deficiency with onset during the antepartum period and can be exacerbated by excessive blood loss at birth. Its prevalence is estimated as 50-80% in low-income and middle-income countries. It poses adverse consequences on the mother and negatively impacts her ability to care for her newborn. Prompt treatment of postpartum anaemia is thus important. Adherence to oral iron is reportedly low in Nigeria due to its side effects and forgetfulness by the mothers. Intravenous iron such as ferric carboxymaltose, given as a single dose, might help overcome adherence issues, but investigation in a high-quality randomised control trial in Nigeria is first required while evaluation of challenges around its implementation is also warranted. OBJECTIVE: To determine the clinical effectiveness, tolerability and safety, of using intravenous ferric carboxymaltose (intervention) vs oral ferrous sulphate (control) for treating moderate to severe iron deficiency anaemia in postpartum women and to evaluate implementation of ferric carboxymaltose in treating postpartum anaemia in Nigeria. METHODS AND ANALYSIS: This study is an open-label randomised controlled trial with a concurrent implementation study. It is a hybrid type 1 effectiveness-implementation design conducted in four states across Northern and Southern Nigeria. A total of 1400 eligible and consenting women with postpartum moderate to severe anaemia (haemoglobin concentration <100 g/L) will be randomised to intravenous ferric carboxymaltose; a single dose at 20 mg/kg to a maximum of 1000 mg infusion administered at enrolment (intervention) or oral ferrous sulphate; 200 mg (65 mg elemental iron) two times per day from enrolment until 6 weeks postpartum (control). The primary outcome, proportion of participants who are anaemic (Hb <110 g/L) at 6 weeks postpartum will be analysed by intention-to-treat. Haemoglobin concentration, full blood count, serum iron, serum ferritin, transferrin saturation and total iron binding capacity will be measured at specific intervals. Implementation outcomes such as acceptability and feasibility of using ferric carboxymaltose for postpartum anaemia treatment in Nigeria will be assessed. ETHICS AND DISSEMINATION: This study is approved by the ethics committee of the teaching hospitals, Ministry of Health of the four states as required, National Health Research Ethics Committee and the drug regulatory agency, National Agency for Food and Drug Administration and Control (NAFDAC). Findings of this research will be presented at conferences and will be published in international peer-reviewed journals and shared with stakeholders within and outside Nigeria. TRIAL REGISTRATION NUMBER: International standard randomised controlled trial number: ISRCTN51426226.
Asunto(s)
Anemia Ferropénica , Compuestos Férricos , Compuestos Ferrosos , Maltosa , Humanos , Femenino , Compuestos Ferrosos/administración & dosificación , Compuestos Ferrosos/uso terapéutico , Maltosa/análogos & derivados , Maltosa/administración & dosificación , Maltosa/uso terapéutico , Compuestos Férricos/administración & dosificación , Compuestos Férricos/uso terapéutico , Nigeria , Anemia Ferropénica/tratamiento farmacológico , Administración Oral , Administración Intravenosa , Embarazo , Periodo Posparto , Ensayos Clínicos Controlados Aleatorios como Asunto , Trastornos Puerperales/tratamiento farmacológico , Adulto , Hematínicos/administración & dosificación , Hematínicos/uso terapéuticoRESUMEN
Our study aims to validate safety and efficacy of Feroglobin capsule compared with different iron supplementations in adult subjects diagnosed with non-anemic to mild anemic iron deficiency and fatigue. Enrolled 302 participants diagnosed with non-anemic to mild anemic iron deficiency and fatigue. Group A (n = 147) received Feroglobin, Group B (n = 146) received standard of care [Haem Up Gems capsules (Ferrous fumarate) or Fericip tablets (Ferrous ascorbate)]. 293 subjects completed the study with follow-up visits on days 30, 60, and 90. Feroglobin treatment significantly increased hemoglobin levels from mean 12.43 g/dl to 13.24 g/dl in 90 days. Ferritin levels improved significantly by 442.87% compared to the standard care's 256.67%. Fatigue scale scores reduced by 47.51%, and all presenting health complaints resolved completely. Gastrointestinal symptoms observed were similar in both the groups. Both groups exhibited moderate treatment adherence. Quality of life improved in pain and general health domains, exhibiting a good tolerability. Adverse events were unrelated to the investigational products. Feroglobin serves as an efficacious therapeutic alternative for improving hemoglobin, ferritin, and reducing fatigue with low doses compared to standard of care. However, longer-term effects of low-dose require further investigations in different target groups.
Asunto(s)
Anemia Ferropénica , Suplementos Dietéticos , Compuestos Ferrosos , Hemoglobinas , Humanos , Femenino , Masculino , Adulto , Persona de Mediana Edad , Hemoglobinas/análisis , Anemia Ferropénica/tratamiento farmacológico , Compuestos Ferrosos/administración & dosificación , Compuestos Ferrosos/uso terapéutico , Calidad de Vida , Hierro/administración & dosificación , Hierro/uso terapéutico , Ferritinas/sangre , Fatiga/tratamiento farmacológico , Fatiga/etiología , Resultado del Tratamiento , AncianoRESUMEN
Effective food fortification strategies using elemental iron powders (EIPs) are needed to combat iron deficiency anemia. The purpose of this study was to determine hemoglobin regeneration efficiency (HRE) and relative iron bioavailability (RBV) of four food-grade EIPs (El-Lyte (EL), Hi-Sol (HS), H-325 (H3), and A-131 (A1)) by treating anemic rats with 14 d iron repletion diets (uncooked and cooked), fortified with a 12, 24, or 36 mg iron/kg diet of the EIPs, ferrous sulfate monohydrate (FS, FeSO4â¢H2O), or no added iron (control), n = 9-12/group. The ability of EL and HS to maintain hemoglobin for 6 weeks on the 6 mg iron/kg diet was also studied. The dissolution rate of iron from the EIPs was measured in hydrochloric acid at pH 1.0. Compared to FS, the EL, HS, and A1 EIPs had >50% overall RBV, with the following order: HS > A1 > EL > H3 (p ≤ 0.05); the effect of cooking was not significant (p > 0.05). Dissolution testing revealed that the mean RBV of the EIPs was positively associated with the percentage of iron solubility. In the 6-week maintenance study, EL and HS maintained hemoglobin as well as FS. Overall, the findings show that at the concentrations of iron tested, these EIPs are effective fortification agents to replenish hemoglobin and correct iron deficiency anemia.
Asunto(s)
Anemia Ferropénica , Disponibilidad Biológica , Alimentos Fortificados , Hemoglobinas , Hierro , Animales , Masculino , Ratas , Anemia Ferropénica/tratamiento farmacológico , Compuestos Ferrosos/administración & dosificación , Hemoglobinas/metabolismo , Hierro/sangre , Hierro de la Dieta/administración & dosificación , Hierro de la Dieta/farmacocinética , Polvos , Ratas Sprague-DawleyRESUMEN
OBJECTIVE: This study aimed to assess the efficacy of different oral iron preparations prescribed for prevention of iron deficiency anemia in healthy infants. METHODS: This retrospective study enrolled infants aged between 6 and 12 months who were initiated on iron prophylaxis at four months of age. Enrolled children consistently used specific iron preparations (ferrous, ferric or liposomal iron) and had their complete blood counts and serum ferritin levels assessed within the 6-12 month timeframe. Blood values and iron prophylaxis type (ferrous (Fe+2), ferric (Fe+3), liposomal iron) were recorded. Chi-square test was used to compare the hemoglobin and ferritin levels levels between groups. Univariate and multivariate regression analyses assessed the risk of anemia. RESULTS: The study included 371 children (ferrous sulphate - 60, iron hydroxide-polymaltose complex - 137 and liposomal ferric pyrophosphate - 174) with a mean (SD) age 9.1 (1.3) mo. Iron deficiency in different groups were: liposomal iron (46.0%), ferric iron (44.5%), and ferrous iron (5.0%). Mean (SD) serum ferritin levels (µg/L) were higher in the ferrous group [30.1 (10.8)] compared to infants receiving ferric [17.6 (14.50)] and liposomal iron [15.4 (12.1)] (P < 0.001). Mean (SD) hemoglobin levels (g/dL) were significantly higher in the ferrous group [12.4 (0.8)] compared to ferric [11.9 (1.1)] and liposomal iron group [12.0 (1.1)]; P =0.008. Multiple regression analysis showed that ferrous group was associated with a lower risk of iron deficiency [OR (95% CI) 0.04 (0.01-0.15), P < 0.001]. CONCLUSION: Ferrous iron demonstrated superior efficacy compared to ferric and liposomal iron. Further studies are needed to establish alternative iron preprations in children.
Asunto(s)
Anemia Ferropénica , Compuestos Férricos , Compuestos Ferrosos , Liposomas , Humanos , Lactante , Anemia Ferropénica/prevención & control , Anemia Ferropénica/sangre , Estudios Retrospectivos , Masculino , Femenino , Compuestos Ferrosos/administración & dosificación , Compuestos Ferrosos/uso terapéutico , Compuestos Férricos/administración & dosificación , Compuestos Férricos/uso terapéutico , Ferritinas/sangre , Hierro/administración & dosificación , Hierro/sangre , Hierro/uso terapéutico , Hemoglobinas/análisis , Hemoglobinas/efectos de los fármacosRESUMEN
This experiment aimed to investigate the effects of dietary iron supplementation from different sources on the reproductive performance of sows and the growth performance of piglets. A total of 87 sows with similar farrowing time were blocked by body weight at day 85 of gestation, and assigned to one of three dietary treatments (nâ =â 29 per treatment): basal diet, basal diet supplemented with 0.2% ferrous sulfate (FeSO4), and basal diet supplemented with 0.2% iron sucrose, respectively, with 30% iron in both FeSO4 and iron sucrose. Compared with the control (CON) group, iron sucrose supplementation reduced the rate of stillbirth and invalid of neonatal piglets (Pâ <â 0.05), and the number of mummified fetuses was 0. Moreover, it also improved the coat color of newborn piglets (Pâ <â 0.05). At the same time, the iron sucrose could also achieve 100% estrus rate of sows. Compared with the CON group, FeSO4 and iron sucrose supplementation increased the serum iron content of weaned piglets (Pâ <â 0.05). In addition, iron sucrose increased serum transferrin level of weaned piglets (Pâ <â 0.05) and the survival rate of piglets (Pâ <â 0.05). In general, both iron sucrose and FeSO4 could affect the blood iron status of weaned piglets, while iron sucrose also had a positive effect on the healthy development of newborn and weaned piglets, and was more effective than FeSO4 in improving the performance of sows and piglets.
Sows need more iron to meet the requirements for their and offspring's growth during pregnancy and lactation. Exogenous iron supplementation may improve the reproductive performance of sows and the growth performance of piglets, but different sources of iron have different effects. This study facilitates the understanding of the effects of iron sucrose and ferrous sulfate on the reproductive performance of sows and the growth performance of piglets.
Asunto(s)
Alimentación Animal , Fenómenos Fisiológicos Nutricionales de los Animales , Dieta , Suplementos Dietéticos , Reproducción , Animales , Femenino , Alimentación Animal/análisis , Dieta/veterinaria , Porcinos/crecimiento & desarrollo , Porcinos/fisiología , Reproducción/efectos de los fármacos , Embarazo , Animales Recién Nacidos , Hierro/administración & dosificación , Hierro/farmacología , Compuestos Ferrosos/farmacología , Compuestos Ferrosos/administración & dosificación , Sacarato de Óxido Férrico/farmacología , Sacarato de Óxido Férrico/administración & dosificación , Hierro de la Dieta/administración & dosificación , Hierro de la Dieta/farmacologíaRESUMEN
Restless legs syndrome (RLS) is a neurological disorder that can have a profound effect on sleep and quality of life. Idiopathic RLS is associated with brain iron insufficiency despite normal peripheral iron stores. There is, however, a five- to six-fold increase in prevalence of RLS in patients with iron deficiency anemia (IDA). Several open-label trials have demonstrated symptomatic improvement in RLS following treatment of IDA using oral or intravenous iron supplementation. To date, there have been no randomized double-blind controlled trials of intravenous iron compared with oral iron for the treatment of RLS patients with IDA. In the current study, oral ferrous sulfate and ferumoxytol were compared for efficacy and speed of response for treatment of RLS occurring in patients with IDA. The planned recruitment for this study was 70 patients with RLS and IDA, to be randomly assigned 1:1 to oral or intravenous iron, using double-blind, double-dummy procedures. At Week 6, the primary outcomes of Clinical Global Impression-Improvement score and change from baseline in the International Restless Legs Syndrome Study Group rating scale score were assessed. Due to challenges, performing the clinical trial during the COVID-19 pandemic, final-week data were found missing for 30 patients. As a result, in order to maintain the prespecified statistical analysis, an additional 30 patients were recruited. Both IV and oral iron were associated with a marked improvement in RLS symptoms, with no statistically significant difference between treatment groups. No serious adverse events were observed in either treatment group.
Asunto(s)
Administración Intravenosa , Anemia Ferropénica , Compuestos Ferrosos , Síndrome de las Piernas Inquietas , Humanos , Síndrome de las Piernas Inquietas/tratamiento farmacológico , Anemia Ferropénica/tratamiento farmacológico , Administración Oral , Método Doble Ciego , Masculino , Femenino , Proyectos Piloto , Persona de Mediana Edad , Compuestos Ferrosos/administración & dosificación , Compuestos Ferrosos/uso terapéutico , Compuestos Ferrosos/efectos adversos , Adulto , Anciano , Resultado del Tratamiento , Óxido Ferrosoférrico/administración & dosificación , Óxido Ferrosoférrico/uso terapéutico , Óxido Ferrosoférrico/efectos adversos , Hierro/administración & dosificación , Hierro/uso terapéuticoRESUMEN
CASE PRESENTATION: An 84-year-old man with an active smoking habit presented to the ED with dyspnea, hemoptysis, and thick phlegm that was difficult to clear. He reported no weight loss, no fever, and no chest pain or dysphonia. He denied both international travel and previous contact with confirmed cases of TB or SARS-CoV-2. He had no known occupational exposures. The patient's personal history included a resolved complete atrioventricular block that required a permanent pacemaker, moderate-to-severe COPD, rheumatoid arthritis (treated with oral prednisone, 2.5 mg/d) and B-chronic lymphocytic leukemia (treated with methotrexate and prophylactic oral supplements of ferrous sulfate). Moreover, he was in medical follow up because of a peptic ulcer, atrophic gastritis, and colonic diverticulosis. The patient also had a history of thoracic surgery after an episode of acute mediastinitis from an odontogenic infection, which required ICU management and temporal tracheostomy.
Asunto(s)
Broncoscopía/métodos , COVID-19/diagnóstico , Compuestos Ferrosos , Enfermedades Pulmonares , Afecciones Crónicas Múltiples/terapia , Aspiración Respiratoria , Anciano de 80 o más Años , Biopsia/métodos , Lavado Broncoalveolar/métodos , COVID-19/epidemiología , Diagnóstico Diferencial , Compuestos Ferrosos/administración & dosificación , Compuestos Ferrosos/efectos adversos , Hematínicos/administración & dosificación , Hematínicos/efectos adversos , Hemoptisis/diagnóstico , Hemoptisis/etiología , Humanos , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/diagnóstico por imagen , Enfermedades Pulmonares/fisiopatología , Enfermedades Pulmonares/terapia , Masculino , Aspiración Respiratoria/complicaciones , Aspiración Respiratoria/diagnóstico , Aspiración Respiratoria/fisiopatología , SARS-CoV-2 , Tomografía Computarizada por Rayos X/métodos , Privación de TratamientoRESUMEN
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder common from childhood to adulthood, affecting 5% to 12% among the general population in developed countries. Potential etiological factors have been identified, including genetic causes, environmental elements and epigenetic components. Nutrition is currently considered an influencing factor, and several studies have explored the contribution of restriction and dietary supplements in ADHD treatments. Iron is an essential cofactor required for a number of functions, such as transport of oxygen, immune function, cellular respiration, neurotransmitter metabolism (dopamine production), and DNA synthesis. Zinc is also an essential trace element, required for cellular functions related to the metabolism of neurotransmitters, melatonin, and prostaglandins. Epidemiological studies have found that iron and zinc deficiencies are common nutritional deficits worldwide, with important roles on neurologic functions (poor memory, inattentiveness, and impulsiveness), finicky appetite, and mood changes (sadness and irritability). Altered levels of iron and zinc have been related with the aggravation and progression of ADHD. OBJECTIVE: This is a systematic review focused on the contribution of iron and zinc in the progression of ADHD among children and adolescents, and how therapies including these elements are tolerated along with its effectiveness (according to PRISMA guidelines). METHOD: The scientific literature was screened for randomized controlled trials published between January 2000 to July 2021. The databases consulted were Medline, PsycINFO, Web of Science, and Google Scholar. Two independent reviewers screened studies, extracted data, and assessed quality and risk of bias (CONSORT, NICE, and Cochrane checklists used). CONCLUSION: Nine studies met the eligibility criteria and were selected. Evidence was obtained regarding the contribution of iron-zinc supplementation in the treatment of ADHD among young individuals. The discussion was focused on how the deficits of these elements contribute to affectation on multiple ADHD correlates, and potential mechanisms explaining the mediational pathways. Evidence also suggested that treating ADHD with diet interventions might be particularly useful for specific subgroups of children and adolescents, but further investigations of the effects of these diet interventions are needed.
Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/dietoterapia , Suplementos Dietéticos , Compuestos Ferrosos/administración & dosificación , Zinc/administración & dosificación , Adolescente , Niño , Compuestos Ferrosos/uso terapéutico , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Zinc/uso terapéuticoRESUMEN
BACKGROUND: Iron deficiency anemia is a widespread problem. Although oral and intravenous therapy are available, iron malabsorption is a distinct possibility. OBJECTIVES: To evaluate the applicability of the oral iron absorption test (OIAT) as a simple and effective means of determining the degree of oral iron absorption. METHODS: The study comprised 81 patients diagnosed with iron deficiency anemia who were referred to a hematology outpatient clinic. Participants were given two ferrous sulphate tablets. Iron levels in the blood were evaluated at intervals from 30 to 180 minutes after iron administration. RESULTS: We divided patients into three distinct groups. The first group consisted of patients with little iron absorption with a maximum iron increment (Cmax) in the blood of 0-49 ug/dl. The second group had a moderate maximum absorption of 50-100 ug/dl, while a third group had considerable absorption of with maximum iron increase of over 100 ug/dl. CONCLUSIONS: The oral iron absorption test, although not clearly standardized, is easy to conduct in any outpatient clinic. This test can readily and clearly determine absorption or nonabsorption of iron. This test can have major implications on the need of oral or intravenous iron therapy and can also determine the need for further gastrointestinal evaluation of the small intestine, where iron absorption takes place and the success of therapy on subsequent iron absorption.
Asunto(s)
Administración Oral , Anemia Ferropénica , Monitoreo de Drogas/métodos , Compuestos Ferrosos , Anemia Ferropénica/diagnóstico , Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/fisiopatología , Disponibilidad Biológica , Femenino , Compuestos Ferrosos/administración & dosificación , Compuestos Ferrosos/sangre , Absorción Gastrointestinal/fisiología , Hematínicos/administración & dosificación , Hematínicos/sangre , Humanos , Síndromes de Malabsorción/diagnóstico , Masculino , Persona de Mediana Edad , Reproducibilidad de los ResultadosRESUMEN
Ferrous sulphate (FS) is a cost effective, readily available iron supplement for iron deficiency (ID). The pro-oxidant effect of oral ferrous iron is known to induce inflammation, causing gastric side-effects and resulting in poor compliance. Curcumin is a potent antioxidant and has also been shown to exhibit iron chelation in-vitro, although it is not established whether these effects are retained in-vivo. The aim of this study was therefore to assess the influence of a formulated bioavailable form of curcumin (HydroCurcTM; 500 mg) on acute iron absorption and status in a double blind, placebo-controlled randomized trial recruiting 155 healthy participants (79 males; 26.42 years ± 0.55 and 76 females; 25.82 years ± 0.54). Participants were randomly allocated to five different treatment groups: iron and curcumin placebo (FS0_Plac), low dose (18 mg) iron and curcumin placebo (FS18_Plac), low dose iron and curcumin (FS18_Curc), high dose (65 mg) iron and curcumin placebo (FS65_Plac), and high dose iron and curcumin (FS65_Curc). Participants were provided with the supplements according to their relevant treatment groups at baseline (0 min), and blood collection was carried out at 0 min and at 180 min following supplementation. In the treatment groups, significant difference was observed in mean serum iron between baseline (0 min) and at end-point (180 min) (F (1, 144) = 331.9, p < 0.0001) with statistically significant intra-group increases after 180 min (p < 0.0001) in the FS18_Plac (8.79 µmol/L), FS18_Curc (11.41 µmol/L), FS65_Plac (19.09 µmol/L), and FS65_Curc (16.39 µmol/L) groups. A significant difference was also observed between the two time points in serum TIBC levels and in whole blood haemoglobin (HGB) in the treatment groups, with a significant increase (1.55%/2.04 g/L) in HGB levels from baseline to end-point observed in the FS65_Curc group (p < 0.05). All groups receiving iron demonstrated an increase in transferrin saturation (TS%) in a dose-related manner, demonstrating that increases in serum iron are translated into increases in physiological iron transportation. This study demonstrates, for the first time, that regardless of ferrous dose, formulated curcumin in the form of HydroCurc™ does not negatively influence acute iron absorption in healthy humans.
Asunto(s)
Absorción Fisiológica/efectos de los fármacos , Curcumina/administración & dosificación , Suplementos Dietéticos , Compuestos Ferrosos/administración & dosificación , Hierro/sangre , Administración Oral , Adulto , Disponibilidad Biológica , Método Doble Ciego , Femenino , Ferritinas/sangre , Voluntarios Sanos , Hemoglobinas/análisis , Humanos , Proteínas de Unión a Hierro/sangre , Masculino , Transferrina/análisisRESUMEN
Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder caused by genetic mutations on TMPRSS6 gene which encodes Matriptase2 (MT2). An altered MT2 cannot appropriately suppress hepatic BMP6/SMAD signaling in case of low iron, hence hepcidin excess blocks dietary iron absorption, leading to a form of anemia resistant to oral iron supplementation. In this study, using the IRIDA mouse model Mask, we characterized homozygous (msk/msk) compared to asymptomatic heterozygous (msk/wt) mice, assessing the major parameters of iron status in different organs, at different ages in both sexes. The effect of carbonyl iron diet was analyzed as control iron supplementation being used for many studies in mice. It resulted effective in both anemic control and msk/msk mice, as expected, even if there is no information about its mechanism of absorption. Then, we mainly compared two forms of oral iron supplement, largely used for humans: ferrous sulfate and Sucrosomial iron. In anemic control mice, the two oral formulations corrected hemoglobin levels from 11.40 ± 0.60 to 15.38 ± 1.71 g/dl in 2-4 weeks. Interestingly, in msk/msk mice, ferrous sulfate did not increase hemoglobin likely due to ferroportin/hepcidin-dependent absorption, whereas Sucrosomial iron increased it from 11.50 ± 0.60 to 13.53 ± 0.64 g/dl mainly in the first week followed by a minor increase at 4 weeks with a stable level of 13.30 ± 0.80 g/dl, probably because of alternative absorption. Thus, Sucrosomial iron, already used in other conditions of iron deficiency, may represent a promising option for oral iron supplementation in IRIDA patients.
Asunto(s)
Anemia Ferropénica/terapia , Compuestos Férricos/uso terapéutico , Compuestos Ferrosos/uso terapéutico , Compuestos de Hierro/uso terapéutico , Hierro de la Dieta/uso terapéutico , Administración Oral , Anemia Ferropénica/metabolismo , Animales , Modelos Animales de Enfermedad , Femenino , Compuestos Férricos/administración & dosificación , Compuestos Ferrosos/administración & dosificación , Humanos , Hierro/metabolismo , Compuestos de Hierro/administración & dosificación , Hierro de la Dieta/administración & dosificación , Masculino , RatonesRESUMEN
Oral iron promotes intestinal tumourigenesis in animal models. In humans, expression of iron transport proteins are altered in colorectal cancer. This study examined whether the route of iron therapy alters iron transport and tumour growth. Colorectal adenocarcinoma patients with pre-operative iron deficiency anaemia received oral ferrous sulphate (n = 15), or intravenous ferric carboxymaltose (n = 15). Paired (normal and tumour tissues) samples were compared for expression of iron loading, iron transporters, proliferation, apoptosis and Wnt signalling using immunohistochemistry and RT-PCR. Iron loading was increased in tumour and distributed to the stroma in intravenous treatment and to the epithelium in oral treatment. Protein and mRNA expression of proliferation and iron transporters were increased in tumours compared to normal tissues but there were no significant differences between the treatment groups. However, intravenous iron treatment reduced ferritin mRNA levels in tumours and replenished body iron stores. Iron distribution to non-epithelial cells in intravenous iron suggests that iron is less bioavailable to tumour cells. Therefore, intravenous iron may be a better option in the treatment of colorectal cancer patients with iron deficiency anaemia due to its efficiency in replenishing iron levels while its effect on proliferation and iron metabolism is similar to that of oral iron treatment.
Asunto(s)
Anemia Ferropénica/complicaciones , Neoplasias Colorrectales/complicaciones , Compuestos Férricos/uso terapéutico , Compuestos Ferrosos/uso terapéutico , Maltosa/análogos & derivados , Administración Intravenosa , Administración Oral , Anciano , Anciano de 80 o más Años , Anemia Ferropénica/metabolismo , Anemia Ferropénica/terapia , Proliferación Celular/efectos de los fármacos , Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/terapia , Femenino , Compuestos Férricos/administración & dosificación , Compuestos Ferrosos/administración & dosificación , Humanos , Hierro/metabolismo , Masculino , Maltosa/administración & dosificación , Maltosa/uso terapéutico , Persona de Mediana EdadRESUMEN
Prevalence of anaemia among Nigerian toddlers is reported to be high, and may cause significant morbidity, affects brain development and function, and results in weakness and fatigue. Although, iron fortification can reduce anaemia, yet the effect on gut microbiota is unclear. This open-label randomised study in anaemic malnourished Nigerian toddlers aimed to decrease anaemia without affecting pathogenic gut bacteria using a multi-nutrient fortified dairy-based drink. The test product was provided daily in different amounts (200, 400 or 600 mL, supplying 2.24, 4.48 and 6.72 mg of elemental iron, respectively) for 6 months. Haemoglobin, ferritin, and C-reactive protein concentrations were measured to determine anaemia, iron deficiency (ID) and iron deficiency anaemia (IDA) prevalence. Faecal samples were collected to analyse gut microbiota composition. All three dosages reduced anaemia prevalence, to 47%, 27% and 18%, respectively. ID and IDA prevalence was low and did not significantly decrease over time. Regarding gut microbiota, Enterobacteriaceae decreased over time without differences between groups, whereas Bifidobacteriaceae and pathogenic E. coli were not affected. In conclusion, the multi-nutrient fortified dairy-based drink reduced anaemia in a dose-dependent way, without stimulating intestinal potential pathogenic bacteria, and thus appears to be safe and effective in treating anaemia in Nigerian toddlers.
Asunto(s)
Anemia Ferropénica/prevención & control , Bebidas , Trastornos de la Nutrición del Niño/prevención & control , Compuestos Ferrosos/administración & dosificación , Alimentos Fortificados , Micronutrientes/administración & dosificación , Anemia Ferropénica/epidemiología , Anemia Ferropénica/microbiología , Trastornos de la Nutrición del Niño/epidemiología , Trastornos de la Nutrición del Niño/microbiología , Preescolar , Productos Lácteos , Relación Dosis-Respuesta a Droga , Femenino , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Lactante , Masculino , Nigeria/epidemiología , PrevalenciaRESUMEN
BACKGROUND: Studies that have compared the effectiveness of oral with intravenous iron supplements to treat postpartum anemia have shown mixed results. The superiority of one mode of treatment vs the other has yet to be demonstrated. Therefore, despite guidelines and standards of care, treatment approaches vary across practices. A single 500 mg dose of iron sucrose, which is higher than what is usually administered, has not been evaluated to treat postpartum moderate to severe anemia. OBJECTIVE: This study aimed to compare the efficacy of intravenous iron sucrose alone with intravenous iron sucrose in combination with oral iron bisglycinate supplementation in treating moderate to severe postpartum anemia. STUDY DESIGN: A randomized controlled trial was conducted between February 2015 and June 2020. Women with postpartum hemoglobin level of ≤9.5 g/dL were treated with 500 mg intravenous iron sucrose after an anemia workup, which ruled out other causes for anemia. In addition to receiving intravenous iron, women were randomly allocated to receive either 60 mg of oral iron bisglycinate for 45 days or no further iron supplementation. The primary outcome was hemoglobin level at 6 weeks after delivery. Secondary outcomes were iron storage parameters and quality of life. RESULTS: Of 158 patients who participated, 63 women receiving intravenous and oral iron, and 44 women receiving intravenous iron-only, completed the study and were included in the analysis. Baseline and obstetrical characteristics were similar between the study cohorts. Although statistically significant, postpartum hemoglobin levels were only 0.4 g/dL higher in the intravenous and oral iron than intravenous iron-only cohort (12.4 g/dL vs 12.0 g/dL, respectively; P=.03), with a respective increase from baseline of 4.2 g/dL vs 3.7 g/dL (P=.03). There was no difference in the rate of women with hemoglobin level of <12.0 or 11.0 g/dL. Iron storage and health quality were not different between the cohorts. Oral iron treatment was associated with 29% rate of adverse effects. Compliance and satisfaction from treatment protocol were high in both cohorts. CONCLUSION: Intravenous 500 mg iron sucrose treatment alone is sufficient to treat postpartum anemia without the necessity of adding oral iron treatment.
Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Compuestos Ferrosos/uso terapéutico , Hematínicos/uso terapéutico , Atención Prenatal , Trastornos Puerperales/tratamiento farmacológico , Administración Oral , Adulto , Femenino , Compuestos Ferrosos/administración & dosificación , Hematínicos/administración & dosificación , Humanos , Infusiones Intravenosas , Embarazo , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: For uncomplicated Plasmodium falciparum malaria, highly efficacious single-dose treatments are expected to increase compliance and improve treatment outcomes, and thereby may slow the development of resistance. The efficacy and safety of a single-dose combination of artefenomel (800 mg) plus ferroquine (400/600/900/1200 mg doses) for the treatment of uncomplicated P. falciparum malaria were evaluated in Africa (focusing on children ≤ 5 years) and Asia. METHODS: The study was a randomized, double-blind, single-dose, multi-arm clinical trial in patients aged > 6 months to < 70 years, from six African countries and Vietnam. Patients were followed up for 63 days to assess treatment efficacy, safety and pharmacokinetics. The primary efficacy endpoint was the polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28 in the Per-Protocol [PP] Set comprising only African patients ≤ 5 years. The exposure-response relationship for PCR-adjusted ACPR at Day 28 and prevalence of kelch-13 mutations were explored. RESULTS: A total of 373 patients were treated: 289 African patients ≤ 5 years (77.5%), 64 African patients > 5 years and 20 Asian patients. None of the treatment arms met the target efficacy criterion for PCR-adjusted ACPR at Day 28 (lower limit of 95% confidence interval [CI] > 90%). PCR-adjusted ACPR at Day 28 [95% CI] in the PP Set ranged from 78.4% [64.7; 88.7%] to 91.7% [81.6; 97.2%] for the 400 mg to 1200 mg ferroquine dose. Efficacy rates were low in Vietnamese patients, ranging from 20 to 40%. A clear relationship was found between drug exposure (artefenomel and ferroquine concentrations at Day 7) and efficacy (primary endpoint), with higher concentrations of both drugs resulting in higher efficacy. Six distinct kelch-13 mutations were detected in parasite isolates from 10/272 African patients (with 2 mutations known to be associated with artemisinin resistance) and 18/20 Asian patients (all C580Y mutation). Vomiting within 6 h of initial artefenomel administration was common (24.6%) and associated with lower drug exposures. CONCLUSION: The efficacy of artefenomel/ferroquine combination was suboptimal in African children aged ≤ 5 years, the population of interest, and vomiting most likely had a negative impact on efficacy. Trial registration ClinicalTrials.gov, NCT02497612. Registered 14 Jul 2015, https://clinicaltrials.gov/ct2/show/NCT02497612?term=NCT02497612&draw=2&rank=1.
Asunto(s)
Adamantano/análogos & derivados , Aminoquinolinas/administración & dosificación , Antimaláricos/administración & dosificación , Compuestos Ferrosos/administración & dosificación , Malaria Falciparum/prevención & control , Metalocenos/administración & dosificación , Peróxidos/administración & dosificación , Plasmodium falciparum/efectos de los fármacos , Adamantano/administración & dosificación , Adolescente , Adulto , Anciano , Benin , Burkina Faso , Niño , Preescolar , Método Doble Ciego , Combinación de Medicamentos , Femenino , Gabón , Humanos , Lactante , Kenia , Masculino , Persona de Mediana Edad , Mozambique , Uganda , Vietnam , Adulto JovenRESUMEN
Background: Congenital anomalies affect millions of babies worldwide with prevalence of 3%, and it is estimated that, globally, 303,000 newborns die within the first 4 weeks of life due to this problem. Objective: This study aimed to assess congenital anomalies and their associated factors among newborns in Bishoftu General Hospital, Oromia Regional State, Ethiopia. Setting. Bishoftu General Hospital, Oromia, Ethiopia. Study Design . A retrospective cross-sectional study was employed. Participants. All birth records from September 14, 2018, to March 14, 2019, were reviewed. A census method was applied for this study. The data were collected from birth registration books through structured checklist. We used Statistical Package for the Social Sciences (SPSS) version 24.0 for data analysis. Crude and adjusted odds ratio with 95% confidence interval was computed. Statistical significance was set at P < 0.05. Result: Out of 2,218 live births, 23 newborns were diagnosed with congenital malformations, making the prevalence rate of 1% (i.e., 10/1000 live births in the specified time period). Maternal age above 35 years (AOR = 6.5; 95% CI = 2.4-18), birth order above 3 (AOR = 8.4; 95% CI = 3.4-20.7), birth weight less than 2.5 kg (AOR = 0.3; 95% CI = 0.1-0.9), and singleton pregnancy (AOR = 6.4; 95% CI = 2-18.9) had a significant association with the incident of congenital anomalies, while iron folate use before and/or during early pregnancy and urban residence (AOR = 0.3; 95% CI = 0.1-1) had a protective effect against congenital anomalies (AOR = 0.036; 95% CI = 0.008-0.15). Conclusion: The findings of this study showed that there is a burden of congenital anomalies in the study area. Sustainable surveillance and registry systems are thus required for intervention programs and it is crucial to include them under Ethiopian demographic health survey (EDHS) report.
Asunto(s)
Anomalías Congénitas/epidemiología , Adulto , Etiopía/epidemiología , Femenino , Compuestos Ferrosos/administración & dosificación , Encuestas Epidemiológicas , Hospitales Generales/estadística & datos numéricos , Humanos , Recién Nacido , Masculino , Edad Materna , Embarazo , Prevalencia , Población Urbana/estadística & datos numéricosRESUMEN
BACKGROUND: Iron deficiency anaemia is a public health problem. In case oral iron treatment is ineffective, poorly tolerated or contraindicated, the intravenous route becomes the first choice. The aim of the study was to evaluate the shift between ferrous gluconate (FG) and ferric carboxymaltose (FCM) usage at our hospitals over the years. We also performed a cost comparison between pre and post-FCM availability periods, taking into account the acquisition costs of both intravenous iron and red blood cell units (PRBC). STUDY DESIGN AND METHODS: The amount and costs of FG and FCM released by hospital Pharmacy Services from 2010 to 2019 were analysed, along with the number of transfused PRBC units in the same timeframe. RESULTS: Overall, the proportion of FCM usage rose from 8.6 % in 2014 to 71.9 % in 2019, as percentage of total intravenous iron released. After exclusion of haemodialysis, where FG is still widely used, the FCM use in the last four years raised from 12.9% to 92.5%. Despite the higher FCM cost, the mean yearly expenditure for intravenous iron plus PRBC units did not differ between pre- and post-FCM eras (2010-2013, 2,396,876 versus 2014-2019, 2,307,875 - pâ¯=â¯0.234), as a result of a net decrease of PRBC usage, namely from 15,083 to 12,654 (-16.1 %), respectively. DISCUSSION: Intravenous iron has a major role in treating iron deficiency anaemia in several settings. Third generation compounds are paving the way to more updated and safer treatments.
Asunto(s)
Anemia Ferropénica , Prescripciones de Medicamentos/economía , Compuestos Férricos , Compuestos Ferrosos , Maltosa/análogos & derivados , Administración Intravenosa , Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/economía , Costos y Análisis de Costo , Femenino , Compuestos Férricos/administración & dosificación , Compuestos Férricos/economía , Compuestos Ferrosos/administración & dosificación , Compuestos Ferrosos/economía , Humanos , Masculino , Maltosa/administración & dosificación , Maltosa/economíaRESUMEN
Oral iron supplementation constitutes the first line treatment for iron deficiency anemia (IDA), with daily doses between 80 mg and 200 mg of elemental iron. Ferrous salts, such as ferrous sulphate (FeSO4), while efficacious, frequently give rise to gastrointestinal side effects. In the present paper we attempted to directly compare the efficacy of an alternative to the FeSO4 formulation, which presents a better tolerability profile, iron protein succinylate (Ferplex®). In a diet-induced anemia model, rats were treated by oral gavage with vehicle, FeSO4, or Ferplex® at a human-dose equivalent of 80 mg and 200 mg of elemental iron. We evaluated the change in anemia-related hematological and biochemical parameters, conducting a histological examination of the intestine at sacrifice. Results indicate that both types of iron supplementation are equally effective in the treatment of IDA, restoring hemoglobin, hematocrit, erythrocytes, free iron and transferrin levels in 15 days, with no statistical differences between treated groups and control. The impact of anemia on body weight was also attenuated following treatment with both iron supplements. Thrombocyte and reticulocyte levels, altered by the anemic condition, returned to homeostasis after 15 days of either FeSO4 or Ferplex® treatment. Importantly, the lower and higher doses of iron were equally effective, thus supporting the current school of thought which states that lower therapeutic doses are sufficient for management of IDA. In addition, the study shows for the first time that oral treatment with Ferplex® does not increase serum hepcidin. Finally, Ferplex® induced minimal iron depositions in the intestinal tissue compared to FeSO4.
Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Compuestos Ferrosos/uso terapéutico , Metaloproteínas/uso terapéutico , Succinatos/uso terapéutico , Animales , Recuento de Eritrocitos , Índices de Eritrocitos , Compuestos Ferrosos/administración & dosificación , Hemoglobinas/análisis , Masculino , Metaloproteínas/administración & dosificación , Ratas , Ratas Sprague-Dawley , Succinatos/administración & dosificaciónRESUMEN
BACKGROUND: Mitochondrial diabetes mellitus (MDM) is characterized by maternal inheritance, progressive neurosensory deafness, insulin secretory disorder, and progressive microvascular complications. Mitochondria are critical organelles that provide energy in the form of adenosine triphosphate (ATP). An impairment of ATP production in pancreatic ß cells is regarded as the main cause of the insulin secretory disorder in patients with MDM, and these patients require insulin replacement therapy early after the diagnosis. The amino acid 5-aminolevulinic acid (5-ALA), a precursor of heme metabolites, is a non-proteinogenic δ amino acid synthesized in mitochondria. An addition of ferrous iron to 5-ALA enhances heme biosynthesis and increases ATP production through an upregulation of the respiratory complex. Several studies have reported that the administration of 5-ALA and ferrous iron to existing treatment improved the glycemic control in both patients with prediabetes and those with type 2 diabetes mellitus. The additional administration of 5-ALA and ferrous iron to MDM patients on insulin therapy may improve their insulin secretory capacity and glycemic control by improving their mitochondrial function. The findings of this study are expected to provide new treatment options for MDM and improve the patients' glycemic control and prognosis. METHODS/DESIGN: This study is a single-arm, open-label pilot intervention study using clinical endpoints to investigate the effects of treatment with 5-ALA plus sodium ferrous citrate (SFC) to patients with MDM on their glucose tolerance. A total of 5 patients with MDM will be administered 5-ALA/SFC (200âmg/d) for 24âweeks. We will perform a 75-g oral glucose tolerance test before and at 24âweeks after the start of this 5-ALA/SFC treatment to evaluate glucose-dependent insulin responses. DISCUSSION: To the best of our knowledge, this study will be the first assessment of the effects of 5-ALA/SFC in patients with MDM. This study will obtain an evidence regarding the effectiveness and safety of 5-ALA/SFC for patients with MDM. TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network (UMIN000040581) on July 1, 2020 and with the Japan Registry of Clinical Trials (jRCTs071200025) on August 3, 2020.
Asunto(s)
Sordera/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Compuestos Ferrosos/administración & dosificación , Intolerancia a la Glucosa/tratamiento farmacológico , Insulina/administración & dosificación , Ácidos Levulínicos/administración & dosificación , Enfermedades Mitocondriales/tratamiento farmacológico , Adenosina Trifosfato/metabolismo , Adulto , Glucemia/análisis , Ácido Cítrico , Sordera/sangre , Sordera/diagnóstico , Sordera/patología , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/patología , Quimioterapia Combinada/efectos adversos , Quimioterapia Combinada/métodos , Femenino , Compuestos Ferrosos/efectos adversos , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/patología , Prueba de Tolerancia a la Glucosa , Humanos , Japón , Ácidos Levulínicos/efectos adversos , Masculino , Mitocondrias/efectos de los fármacos , Mitocondrias/patología , Enfermedades Mitocondriales/sangre , Enfermedades Mitocondriales/diagnóstico , Enfermedades Mitocondriales/patología , Proyectos Piloto , Resultado del Tratamiento , Ácido AminolevulínicoRESUMEN
BACKGROUND: Long-term feeding of prebiotic galacto-oligosaccharides (GOS) increases iron absorption in African infants, but the underlying mechanism and how long GOS need to be fed to infants to achieve an increase in absorption is uncertain. OBJECTIVES: In Kenyan infants, we tested whether the addition of GOS to a single test meal would affect iron absorption from a micronutrient powder (MNP) containing ferrous sulfate (FeSO4) and another MNP containing ferrous fumarate (FeFum) and sodium iron ethylenediaminetetraacetate (NaFeEDTA). METHODS: In a randomized-entry, prospective crossover study, iron deficient (87%) and anemic (70%) Kenyan infants (n = 23; mean ± SD age, 9.9 ± 2.1 months) consumed 4 stable iron isotope-labeled maize porridge meals fortified with MNPs containing 5 mg iron as FeFum + NaFeEDTA, or FeSO4, either without or with 7.5 g GOS. The primary outcome, fractional iron absorption (FIA), was assessed by erythrocyte incorporation of isotopic labels. Data were analyzed using a 2-way repeated-measures ANOVA. RESULTS: There was no significant interaction between GOS and the iron compounds on FIA, and the addition of GOS did not have a significant effect on FIA. There was a statistically significant difference in FIA between the meals fortified with FeSO4 and with FeFum + NaFeEDTA (P < 0.001).Given with GOS, FIA from FeSO4 was 40% higher than from FeFum + NaFeEDTA (P < 0.001); given without GOS, it was 51% higher (P < 0.01). CONCLUSIONS: The addition of GOS to a single iron-fortified maize porridge test meal in Kenyan infants did not significantly increase iron absorption, suggesting long-term feeding of GOS may be needed to enhance iron absorption at this age. This study was registered at clinicaltrials.gov as NCT02666417.